Hertraz (Trastuzumab) 440 mg is a monoclonal antibody used in the treatment of HER2-positive breast cancer and metastatic gastric cancer. It specifically targets the HER2 receptor, a protein found in high levels on some cancer cells, and works by inhibiting cell proliferation and promoting immune-mediated destruction of tumor cells. Hertraz is administered via intravenous infusion under the supervision of an oncologist.

• Targets and inhibits HER2-positive cancer cells

• Enhances the efficacy of chemotherapy in combination therapy

• Helps slow disease progression and improves survival rates

• Effective in both early-stage and metastatic HER2-positive cancers

• Personalized therapy with targeted action and monitored dosing

Hertraz is not for self-administration. It is administered as an IV infusion in a clinical setting by trained medical professionals. The first infusion is given over 90 minutes, with subsequent doses over 30 minutes if well-tolerated.

• Loading dose: 8 mg/kg body weight as an IV infusion

• Maintenance dose: 6 mg/kg every 3 weeks

• Dosage may vary based on body weight and treatment response

• Often used in combination with chemotherapy or other targeted therapies

• Cardiac monitoring (e.g., echocardiogram) is required during treatment due to risk of heart failure

• Not recommended during pregnancy or breastfeeding

• Use caution in patients with pre-existing heart conditions

• Report symptoms like breathlessness, chest pain, or swelling in extremities immediately

• Common side effects include fever, chills, nausea, headache, diarrhea, and infusion reactions. Serious side effects may involve cardiotoxicity, allergic reactions, or pulmonary events. Any adverse symptoms should be reported to the healthcare provider immediately.

   

Store vials in a refrigerator at 2°C to 8°C. Do not freeze or shake. Reconstituted solution should be used as per healthcare provider’s guidelines under aseptic conditions. Keep out of reach of children.

Q1: What is Hertraz 440 mg used for?
A1: Hertraz is used to treat HER2-positive breast cancer and metastatic gastric cancer by targeting HER2 receptors on cancer cells.

Q2: How is Hertraz given?
A2: It is administered as an intravenous infusion under medical supervision, typically every 3 weeks.

Q3: Can Hertraz cause heart problems?
A3: Yes, it may affect heart function. Regular cardiac monitoring is essential during treatment.

Q4: Is Hertraz chemotherapy?
A4: No, it is a targeted therapy, but it is often used alongside chemotherapy for better efficacy.

Q5: Can pregnant women use Hertraz?
A5: No, Hertraz is not recommended during pregnancy due to potential harm to the fetus.